Literature DB >> 32414650

Commentary. Toward a core outcomes assessment set for clinical high risk.

Scott W Woods1, Catalina V Mourgues-Codern2, Albert R Powers3.   

Abstract

Entities:  

Keywords:  Clinical high risk; Core outcomes set; Drug development; Functioning; Psychometrics; Symptoms

Mesh：

Year:  2020        PMID： 32414650      PMCID： PMC8215729          DOI： 10.1016/j.schres.2020.05.008

Source DB:  PubMed          Journal:  Schizophr Res        ISSN： 0920-9964            Impact factor:   4.939


× No keyword cloud information.
  30 in total

1.  Priorities of consumers, providers, and family members in the treatment of schizophrenia.

Authors:  Ellen P Fischer; Martha Shumway; Richard R Owen
Journal:  Psychiatr Serv       Date:  2002-06       Impact factor: 3.084

Review 2.  Taking Psychiatry Research Online.

Authors:  Claire M Gillan; Nathaniel D Daw
Journal:  Neuron       Date:  2016-07-06       Impact factor: 17.173

3.  Valuation and attainment of treatment goals in schizophrenia: perspectives of patients, relatives, physicians, and payers.

Authors:  Olaf Kuhnigk; Lara Slawik; Jelka Meyer; Dieter Naber; Jens Reimer
Journal:  J Psychiatr Pract       Date:  2012-09       Impact factor: 1.325

4.  Clinical and functional characteristics of youth at clinical high-risk for psychosis who do not transition to psychosis.

Authors:  Jean Addington; Jacqueline Stowkowy; Lu Liu; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Carrie E Bearden; Daniel H Mathalon; Olga Santesteban-Echarri; Scott W Woods
Journal:  Psychol Med       Date:  2018-09-04       Impact factor: 7.723

5.  The "prodromal" patient: both symptomatic and at-risk.

Authors:  S W Woods; T J Miller; T H McGlashan
Journal:  CNS Spectr       Date:  2001-03       Impact factor: 3.790

6.  Reliability of a patient-reported outcome measure in schizophrenia: Results from back-to-back self-ratings.

Authors:  Hiroyoshi Takeuchi; Gagan Fervaha; Gary Remington
Journal:  Psychiatry Res       Date:  2016-07-27       Impact factor: 3.222

7.  Limitations of the Hamilton Anxiety Rating Scale as a primary outcome measure in randomized, controlled trials of treatments for generalized anxiety disorder.

Authors:  Naomi Koerner; Martin M Antony; Michel J Dugas
Journal:  Am J Psychiatry       Date:  2010-01       Impact factor: 18.112

Review 8.  Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A).

Authors:  Laura J Julian
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

9.  Modeling perception and behavior in individuals at clinical high risk for psychosis: Support for the predictive processing framework.

Authors:  Eren Kafadar; Vijay A Mittal; Gregory P Strauss; Hannah C Chapman; Lauren M Ellman; Sonia Bansal; James M Gold; Ben Alderson-Day; Samuel Evans; Jamie Moffatt; Steven M Silverstein; Elaine F Walker; Scott W Woods; Philip R Corlett; Albert R Powers
Journal:  Schizophr Res       Date:  2020-06-24       Impact factor: 4.939

10.  Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis.

Authors:  Paolo Fusar-Poli; Barnaby Nelson; Lucia Valmaggia; Alison R Yung; Philip K McGuire
Journal:  Schizophr Bull       Date:  2012-11-22       Impact factor: 9.306
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.